Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emiplacel - Pluri

Next Previous
Drug Profile

Emiplacel - Pluri

Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; PLacental eXpanded cells; PLX PAD; PLX-PAD cell therapy

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pluristem Therapeutics
  • Developer Pluri; Tel-Aviv Ichilov Medical Center
  • Class Ischaemic heart disorder therapies; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic limb-threatening ischemia; Muscle injury
  • Phase II Intermittent claudication; SARS-CoV-2 acute respiratory disease
  • Phase I/II Graft-versus-host disease
  • No development reported Duchenne muscular dystrophy; Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries; Thromboangiitis obliterans

Most Recent Events

  • 02 Feb 2026 Emiplacel is still in phase-III trial in Muscle injury (In the elderly, In adults, In neonates, In infants, In children, In adolescents) in USA, Bulgaria, Denmark, Germany, United Kingdom and Israel (IM) (NCT03451916)
  • 08 Apr 2024 Pluri has patent protection for System and Methods for Immune Cells Expansion and Activation in Large Scale in the US
  • 06 Sep 2023 Pluristem completes a phase III trial for Muscle injury (In the elderly, In adults, In neonates, In infants, In children, In adolescents) in USA, Bulgaria, Denmark, Germany, United Kingdom and Israel (IM) (NCT03451916)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top